We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
SRNE at $1.90 -- Target Price Issued at $20!
An SI Board Since July 2017
Posts SubjectMarks Bans Symbol
4 1 0 SRNE
Emcee:  albertaft Type:  Moderated
Very large target prices coming in on SRNE currently at $1.90. Some of the largest around with an average target of $20. No doubt that there is an inside scoop of big things happening.

Sorrento Therapeutics (NASDAQ: SRNE)

FBR Capital analyst Edward White reiterated a Buy rating on Sorrento Therapeutics (NASDAQ: SRNE) yesterday. The company’s shares opened today at $1.90, close to its 52-week low of $1.50.

According to, White is a 2-star analyst with an average return of 0.3% and a 43.5% success rate. White covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Spectrum Pharmaceuticals, and RXi Pharmaceuticals Corp.

Currently, the analyst consensus on Sorrento Therapeutics is Moderate Buy and the average price target is $20, representing a 952.6% upside.

In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $20 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions.

Note -- The Wall Street Jo0urnal is also issuing a target of $20.

Any thoughts? Seems like big things are happening, or are about to happen.
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):